Enliven Therapeutics Inc (ELVN) has a current Price-to-Book (P/B) ratio of 1.93. Compared to its 3-year average P/B ratio of 2.73, the current P/B ratio is approximately -29.23% higher. Relative to its 5-year average P/B ratio of 2.69, the current P/B ratio is about -28.07% higher. Enliven Therapeutics Inc (ELVN) has a Forward Free Cash Flow (FCF) yield of approximately -7.79%. Compared to its 3-year average FCF yield of -7.07%, the current FCF yield is approximately 10.22% lower. Relative to its 5-year average FCF yield of -7.04%, the current FCF yield is about 10.61% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ELVN competitors is 18567.23, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN.O) exhibits a P/S ratio of 111115.34, which is 498.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ELVN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ELVN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ELVN currently overvalued or undervalued?

What is Enliven Therapeutics Inc (ELVN) fair value?

ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Enliven Therapeutics Inc (ELVN) is between 26.48 to 38.50 according to relative valuation method.

How does ELVN's valuation metrics compare to the industry average?

The average P/S ratio for ELVN's competitors is 18567.23, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN) exhibits a P/S ratio of 111115.34, which is 498.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Enliven Therapeutics Inc (ELVN) as of Mar 03 2026?

As of Mar 03 2026, Enliven Therapeutics Inc (ELVN) has a P/B ratio of 1.93. This indicates that the market values ELVN at 1.93 times its book value.

What is the current FCF Yield for Enliven Therapeutics Inc (ELVN) as of Mar 03 2026?

As of Mar 03 2026, Enliven Therapeutics Inc (ELVN) has a FCF Yield of -7.79%. This means that for every dollar of Enliven Therapeutics Inc's market capitalization, the company generates -7.79 cents in free cash flow.

What is the current Forward P/E ratio for Enliven Therapeutics Inc (ELVN) as of Mar 03 2026?

As of Mar 03 2026, Enliven Therapeutics Inc (ELVN) has a Forward P/E ratio of -8.87. This means the market is willing to pay $-8.87 for every dollar of Enliven Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Enliven Therapeutics Inc (ELVN) as of Mar 03 2026?

As of Mar 03 2026, Enliven Therapeutics Inc (ELVN) has a Forward P/S ratio of 111115.34. This means the market is valuing ELVN at $111115.34 for every dollar of expected revenue over the next 12 months.

ELVN Valuation